Analysts Issue Forecasts for Teva Pharmaceutical Industries Ltd’s Q1 2018 Earnings (TEVA)

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) – Equities researchers at Jefferies Group issued their Q1 2018 EPS estimates for shares of Teva Pharmaceutical Industries in a research note issued to investors on Tuesday. Jefferies Group analyst D. Steinberg forecasts that the company will earn $0.58 per share for the quarter. Jefferies Group currently has a “Hold” rating and a $19.00 target price on the stock. Jefferies Group also issued estimates for Teva Pharmaceutical Industries’ Q2 2018 earnings at $0.52 EPS, Q3 2018 earnings at $0.49 EPS and Q4 2018 earnings at $0.51 EPS.

How to Become a New Pot Stock Millionaire

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Thursday, February 8th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.14. Teva Pharmaceutical Industries had a positive return on equity of 16.43% and a negative net margin of 72.66%. The business had revenue of $5.46 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same quarter last year, the firm earned $1.38 earnings per share. The company’s revenue for the quarter was down 15.9% compared to the same quarter last year.

TEVA has been the subject of a number of other research reports. Goldman Sachs upgraded Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and set a $20.00 target price for the company in a research note on Friday, December 15th. Cantor Fitzgerald set a $18.00 target price on Teva Pharmaceutical Industries and gave the company a “hold” rating in a research note on Thursday, December 28th. BTIG Research set a $16.00 target price on Teva Pharmaceutical Industries and gave the company a “buy” rating in a research note on Tuesday, November 28th. ValuEngine downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Friday, February 2nd. Finally, Vetr downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating and set a $21.73 price target for the company. in a report on Monday, March 12th. Eleven research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and seven have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $20.58.

Shares of Teva Pharmaceutical Industries stock opened at $16.91 on Thursday. The company has a quick ratio of 0.58, a current ratio of 0.86 and a debt-to-equity ratio of 1.91. Teva Pharmaceutical Industries has a 12 month low of $10.85 and a 12 month high of $33.82. The stock has a market capitalization of $17,897.04, a PE ratio of -1.04, a PEG ratio of 1.53 and a beta of 0.65.

In other Teva Pharmaceutical Industries news, EVP Mark Sabag sold 5,050 shares of the stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $19.68, for a total transaction of $99,384.00. Following the transaction, the executive vice president now owns 44,517 shares of the company’s stock, valued at approximately $876,094.56. The transaction was disclosed in a document filed with the SEC, which is available at this link. In the last ninety days, insiders have sold 10,734 shares of company stock worth $204,795. 7.10% of the stock is currently owned by company insiders.

Institutional investors have recently made changes to their positions in the company. Calton & Associates Inc. acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $108,000. Fieldpoint Private Securities LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth approximately $171,000. Global Financial Private Capital LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $193,000. Wetherby Asset Management Inc. acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $197,000. Finally, Sigma Planning Corp acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $214,000. Institutional investors and hedge funds own 58.19% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3294450/analysts-issue-forecasts-for-teva-pharmaceutical-industries-ltds-q1-2018-earnings-teva.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Atlantic Capital  Receiving Somewhat Favorable Press Coverage, Accern Reports
Atlantic Capital Receiving Somewhat Favorable Press Coverage, Accern Reports
Foresight Energy  Receives Daily Media Sentiment Rating of -0.02
Foresight Energy Receives Daily Media Sentiment Rating of -0.02
Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Park-Ohio  Stock Price
Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Park-Ohio Stock Price
Ribbon Communications Inc  Receives $7.56 Consensus PT from Analysts
Ribbon Communications Inc Receives $7.56 Consensus PT from Analysts
Analysts Set Progressive Co.  Price Target at $53.43
Analysts Set Progressive Co. Price Target at $53.43
Brokerages Set Fortune Brands Home & Security  Target Price at $73.62
Brokerages Set Fortune Brands Home & Security Target Price at $73.62


© 2006-2018 Ticker Report. Google+.